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Medication shortages can create considerable disruptions in patient care depending 
on the availability of suitable therapeutic alternatives.  Recently, the manufacturer 
of belatacept announced an impending shortage which could impact patient 
management at many transplant centers worldwide.  Belatacept received Food and 
Drug Administration (FDA) and European Medicines Agency approval in 2011, 
with an indication for de-novo use following renal transplant.  However, in many 
transplant centers, it has found use off label in conversion from calcineurin 
inhibitor (CNI)-based therapies.  Although the use of belatacept in the US is not 
reported in the most recent OPTN/SRTR Kidney Annual Data Report, it is 
believed by the authors that this agent is gaining traction in all approved countries 
as an alternative to or in conjunction with reduced doses of traditional maintenance 
immunosuppressants.(1) 
 
Like most biologic agents, the manufacturing of belatacept is difficult, time-
consuming and expensive.  To this end, the manufacturer of belatacept has been 
transitioning to a more efficient and higher yielding manufacturing process.  
Unfortunately, this transition has experienced a significant delay, but the reasons 
for this setback are unknown.  It is important to note that the FDA mandates that 
when a change is made in drug manufacturing, prior to its approval for distribution, 
the manufacturer must validate any changes in identity, strength, quality, purity, 
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and potency of the drug to assure there is no change in pharmacokinetics, safety or 
efficacy.(2)  Based on the belatacept manufacturing delay, along with the growth 
in new prescriptions, the manufacturer anticipates that the current supply of 
belatacept will not be adequate to facilitate its use in new patients.  To preserve the 
current supply for existing belatacept-treated patients, the manufacturer established 
a restrictive distribution program.  All patients currently receiving belatacept must 
be registered with the distribution program to continue to have access to this drug 
after March 15, 2017.  The manufacturer anticipates that, subject to regulatory 
approval, the transition to the new manufacturing process will be successfully 
completed in late 2017, resulting in a significant increase in supply that will be 
able to sustain both existing and new patients starting in 2018. 
 
Despite its slow up-take in many transplant centers since its regulatory approval, 
belatacept has positioned itself as an alternative to both CNI and mammalian target 
of rapamycin (mTOR) inhibitors.  Patients that have used belatacept de-novo or via 
conversion may have experienced similar graft survival, however with better 
kidney transplant function. Treatment with belatacept is also associated with 
improved blood pressure and lipid profiles, as well as less diabetes when compared 
to CNI based regimens.(3, 4)  Not having belatecept available as an alternative to 
traditional immunosuppression, even for several months, could therefore 
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significantly impact the management of transplant recipients.  It is understood why 
the manufacturer felt the need to implement the belatacept distribution program, 
but such a program places a burden on transplant clinicians and center personnel.  
Managing the proper movement of patient-specific supplies and communication 
with transplant physicians, pharmacists, coordinators, infusion centers and patients 
will provide a challenge to transplant centers.   
 
Overall, it has been well documented that both the United States and Europe have 
experienced an increased frequency of drug shortages, which have resulted in 
difficulties for patients, practitioners, health care facilities, and even federal 
regulators.(5-7) There are many factors that contribute to drug shortages, including 
reduced availability of raw materials, manufacturing difficulties, regulatory issues, 
and manufacturer marketing decisions, to name a few.  Importantly, tendering, as a 
method of cost-containment, has also been identified as a cause of drug shortages. 
Tendering is a process in which payers (ie, private or government insurance), 
negotiates the lowest price for a medication with multiple producers.  The supplier 
offers the lowest price has their medications available on the payers’ insurance 
plans for the duration of the contract.  The low drug prices resulting from tendering 
can reduce the number of suppliers, making drugs more susceptible to shortages.  
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Production of pharmaceuticals is becoming more and more concentrated, to 
increase efficiency.  Thus, there may be only 1 active producer worldwide.  If this 
sole production site has a problem, it immediately becomes a global issue. 
Additionally, due to the complexity of the production process, high quality 
requirements and small margin for errors, injectable drugs may be more 
susceptible to manufacturing problems or quality issues than capsules or tablets.(5-
7) 
 
Currently, drug shortages span across all major therapeutic areas, and medications 
used in solid organ transplantation are no exception.  In the United States over the 
past 10 years alone, almost every major transplant immunosuppressant has been 
affected by a drug shortage (8): 
 
Intravenous methylprednisolone (2000-2011; frequent shortages due to decreased 
production by several manufacturers)  
 
Intravenous cyclosporine (2011; shortage due to manufacturer discontinuation)  
 
Cyclosporine modified capsules (2012; shortage due to manufacturing delays)  
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Enteric-coated mycophenolic acid tablets (2012; no known reason for shortage)  
 
Alemtuzumab (2012; shortage due to the drug being voluntarily withdrawn from 
the market and a restrictive distribution program being initialized for its use in 
organ transplantation)  
 
Azathioprine tablets (2015; shortage due to manufacturer discontinuation) 
 
Tacrolimus capsules (2015; shortage due to manufacturer discontinuation and 
manufacturing delays) 
 
Intravenous azathioprine (2016; shortage due to discontinuation by the lone 
manufacturer) 
 
Over a similar period, transplant centers have also experienced shortages in 
sulfamethoxazole-trimethoprim, ganciclovir, acyclovir, and intravenous 
immunoglobulin.   
 
One of the biggest differences between many of the shortages listed above and the 
current belatacept shortage is the up-front communication of this issue by the 
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manufacturer to transplant practitioners and the institution of a restrictive 
distribution program to ensure that preexisting belatacept-treated patients remain 
on this medication.  Although not being able to use belatacept in new transplant 
patients until the manufacturing transition is complete is far from ideal, with the 
steps taken by the manufacturer, transplant practitioners have had the time to take 
care of existing patients and plan for future patients.   
 
In June 2013, the International Pharmaceutical Federation convened an 
International Summit on Medicine Shortage.   A large number of solutions and best 
practices to prevent and mitigate shortages are suggested, both on the demand and 
supply side.(9)  However, it is to be expected that drug shortages will continue to 
have a significant impact on patient management, including organ transplant 
recipients. Moving forward, manufacturers can help mitigate drug shortages 
through proper communication with federal agencies when changes in 
manufacturing processes or shortages in raw materials are noted.  For practitioners, 
it is imperative that they be cognizant of current shortages, and adequately respond 
to new shortages of transplant immunosuppressants.  
 
  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
8 
 
REFERENCES 
1. Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 annual data report: 
kidney. Am J Transplant. [published online January 3 2017]. doi: 
10.1111/ajt.14124. 
2. Food and Drug Administration.  Guidance for industry changes to an 
approved NDA or ANDA. 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformatio
n/Guidances/UCM077097.pdf.  Updated September 2009.  Accessed March 9, 
2017. 
3. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes 
in kidney transplantation. N Engl J Med. 2016; 374(4):333-43. 
4. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin 
inhibitor-based regimens to a belatacept-based regimen in renal transplant 
recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011; 6(2):430-9. 
5. Gupta DK, Huang SM. Drug shortages in the United States: a critical 
evaluation of root causes and the need for action. Clin Pharmacol Ther. 2013; 
93(2):133-5. 
6. Pauwels K, Simoens S, Casteels M, Huys I. Insights into European drug 
shortages: a survey of hospital pharmacists. PLoS One. 2015; 10(3):e0119322. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
9 
 
7. Krisl JC, Fortier CR, Taber DJ. Disruptions in the supply of medications 
used in transplantation: implications and management strategies for the transplant 
clinician. Am J Transplant. 2013; 13(1):20-30. 
8. American Society of Health-System Pharmacists. Current Drug Shortages. 
https://www.ashp.org/drug-shortages/current-shortages.  Updated March 2017.  
Accessed March 9, 2017. 
9. International Pharmaceutical Federation. Report of the International Summit 
on Medicines Shortage.  
https://www.fip.org/files/fip/publications/FIP_Summit_on_Medicines_Shortage.pd
f.  Updated September 2013.  Accessed March 9, 2017. 
 
 
AC
CE
PT
ED
